Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.
In this study we investigated the pharmacological properties of MEN 11149, 2-(2-naphthyl)-1-N-[(1R,2S)-2-N-[1(H)indol-3-ylcarbonyl]aminocy clohexanecarbonyl]-1-[N'-methyl-N'-(4-methylphenylacetyl)]di aminoethane, a novel partially retro-inverse pseudo peptide antagonist of tachykinin NK1 receptors. MEN 11149 potently inhibits the binding of [3H]substance P to tachykinin NK1 sites in IM9 cells (pKi = 8.5 +/- 0.1). The compound is highly specific for the human tachykinin NK1 receptors, since it has negligible effects (pKi < 6) on the binding of specific ligands to tachykinin NK2, NK3 receptors and a battery of central and peripheral receptors or ion channels. The tachykinin NK1 receptor antagonism of MEN 11149 appears to be insurmountable since, in saturation binding experiments, both K(D) and Bmax are significantly affected by incubation with the compound (1-30 nM). In isolated guinea-pig ileum, MEN 11149 (0.1-100 nM) shifts to the right in a non-parallel way the substance P methyl ester-induced cumulative concentration-response curve with progressive inhibition of the maximal response (pK(B) = 9.6 +/- 0.1). When tested for reversibility at 5 nM in the same preparation, the compound displays a slow dissociation rate compared to the fast dissociation rate with FK888 (N2-[(4R)-4-hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl]-N-methy l-N-phenylmethyl-L-3-(2-naphthyl)alaninamide) at 5 nM. In the same preparation, MEN 11149 (10 microM) did not affect the cumulative concentration-response curve to acetylcholine. In vivo, MEN 11149 dose dependently antagonizes [Sar9,Met(O2)11]substance P-induced bronchoconstriction in anaesthetized guinea-pigs (ID50 = 83 +/- 31 nmol/kg i.v.). The duration of the effect exceeds 3 h. MEN 11149 does not affect the bronchoconstriction induced by neurokinin A. The compound dose dependently inhibits [Sar9,Met(O2)11]substance P-induced plasma protein extravasation in guinea-pig bronchi whether administered intravenously (ID50 = 0.22 +/- 0.02 micromol/kg) or orally (ID50 = 0.97 +/- 0.21 micromol/kg). These results demonstrate that MEN 11149 is a potent, highly selective and orally effective insurmountable antagonist of tachykinin NK1 receptors with a long duration of action.
Cirillo
R
R
Pharmacology Department, Menarini Ricerche, Pomezia, Italy.
Astolfi
M
M
Conte
B
B
Lopez
G
G
Parlani
M
M
Terracciano
R
R
Fincham
C I
CI
Manzini
S
S
D000284:Administration, Oral; D000818:Animals; D001798:Blood Proteins / Q000187:drug effects; D016084:Bronchoconstriction / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D007082:Ileum / Q000187:drug effects* / Q000502:physiology; D007211:Indoles / Q000494:pharmacology*; D007473:Ion Channels / Q000187:drug effects; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009281:Naphthalenes / Q000494:pharmacology*; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors* / Q000187:drug effects; D013373:Substance P / Q000378:metabolism / Q000494:pharmacology; D015320:Tachykinins / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D001798:Blood Proteins; D007211:Indoles; D007473:Ion Channels; C111883:MEN 11149; D009281:Naphthalenes; D018039:Receptors, Tachykinin; D015320:Tachykinins; D013373:Substance P